Evorpacept

Generic Name: Evorpacept

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2484949-51-9

Unique Ingredient Identifier: X7K762X1IJ

Background: evorpacept is under investigation in clinical trial NCT04755244 (A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

Phase 2

Recruiting

Conditions: Oropharynx Cancer

Interventions: Drug: Evorpacept

First Posted Date: 2023-03-28

Last Posted Date: 2024-03-01

Lead Sponsor: University of California, San Diego

Target Recruit Count: 29

Registration Number: NCT05787639

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

Phase 1

Recruiting

Conditions: Bladder Cancer
Urothelial Carcinoma

Interventions: Drug: Evorpacept
Drug: Enfortumab Vedotin

First Posted Date: 2022-09-01

Last Posted Date: 2024-03-22

Lead Sponsor: ALX Oncology Inc.

Target Recruit Count: 30

Registration Number: NCT05524545

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

and more 6 locations

A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Phase 1

Active, not recruiting

Conditions: HER2-expressing Cancers

Interventions: Drug: Zanidatamab
Drug: Evorpacept

First Posted Date: 2021-08-30

Last Posted Date: 2024-12-13

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT05027139

Locations: 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Astera Cancer Care, East Brunswick, New Jersey, United States
🇺🇸
UC San Diego - Moores Cancer Center, La Jolla, California, United States

and more 8 locations

A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
AML, Adult

Interventions: Drug: evorpacept
Drug: venetoclax
Drug: azacitidine

First Posted Date: 2021-02-16

Last Posted Date: 2024-11-27

Lead Sponsor: ALX Oncology Inc.

Target Recruit Count: 14

Registration Number: NCT04755244

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

and more 2 locations

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Phase 2

Active, not recruiting

Conditions: Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: pembrolizumab
Drug: evorpacept
Drug: Cisplatin/Carboplatin; 5FU

First Posted Date: 2020-12-19

Last Posted Date: 2024-07-22

Lead Sponsor: ALX Oncology Inc.

Target Recruit Count: 172

Registration Number: NCT04675333

Locations: 🇺🇸
University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Oregon Health & Science University/ Knight Cancer Institute, Portland, Oregon, United States

and more 41 locations

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Phase 2

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer

Interventions: Drug: evorpacept
Drug: pembrolizumab

First Posted Date: 2020-12-19

Last Posted Date: 2024-07-22

Lead Sponsor: ALX Oncology Inc.

Target Recruit Count: 189

Registration Number: NCT04675294

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, Newark, New Jersey, United States
🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium

and more 49 locations

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Phase 1

Recruiting

Conditions: Plasma Cell Myeloma Refractory

Interventions: Drug: Isatuximab
Drug: Dexamethasone
Drug: Pegenzileukin
Drug: Evorpacept
Drug: Pomalidomide
Drug: SAR439459
Drug: Belantamab mafodotin
Drug: Belumosudil

First Posted Date: 2020-11-24

Last Posted Date: 2024-07-05

Lead Sponsor: Sanofi

Target Recruit Count: 197

Registration Number: NCT04643002

Locations: 🇮🇱
Investigational Site Number : 3760002, Jerusalem, Israel
🇫🇷
Investigational Site Number : 2500002, Lille, France
🇫🇷
Investigational Site Number : 2500001, Nantes, France

and more 20 locations

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Phase 1

Active, not recruiting

Conditions: Higher Risk Myelodysplastic Syndromes

Interventions: Drug: azacitidine
Drug: evorpacept

First Posted Date: 2020-06-04

Last Posted Date: 2023-08-14

Lead Sponsor: ALX Oncology Inc.

Target Recruit Count: 65

Registration Number: NCT04417517

Locations: 🇺🇸
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
IU Simon Cancer Center, Indianapolis, Indiana, United States

and more 16 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy